DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.

Trial Details

NCT ID
NCT07059650
Phase
PHASE1 / PHASE2
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • DZD8586+R-CHOP
  • DZD8586+R-GemOx
  • DZD8586+BR
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087
  • Chengdu, China|30.66667,104.06667
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.
  • Disease stage II to IV by Ann Arbor Classification.
  • Life expectancy ≥ 12 months.
  • Cohort 2, 3:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →